by Jordana Choucair | Jan 4, 2023 | Life Sciences
Gilead Sciences Inc. and EVOQ Therapeutics Inc. are partnering to develop autoimmune disorder treatments in a deal worth up to $658.5 million. The companies will collaborate on preclinical work for rheumatoid arthritis and lupus treatments, and Gilead will then...
by Jordana Choucair | Jan 4, 2023 | M&A
The Oregon Health Authority (OHA) approved Amazon’s proposed acquisition of One Medical after conducting a regulatory review. The regulator concluded the acquisition would be unlikely to affect access and cost for Oregonians and ruled out a more comprehensive review...
by Jordana Choucair | Jan 4, 2023 | Payers
The U.S. Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released a report revealing that Medicare lost out on millions of potential savings due to spotty oversight of the average sales price (ASP) of medications. According to the...
by Jordana Choucair | Jan 4, 2023 | Transition to Value
A new study published in JAMA Health Forum found that physician group practices don’t fare quite as well as hospitals in bundled payment arrangements. While hospitals participating in the Bundled Payments for Care Improvement (BPCI) Initiative saved money for both the...
by Jordana Choucair | Jan 3, 2023 | Life Sciences
The House Oversight and Energy and Commerce committees released a report revealing that the Food and Drug Administration’s (FDA) approval for Alzheimer’s drug Aduhelm was “rife with irregularities.” According to the 18-month investigation, officials didn’t...
by Jordana Choucair | Jan 3, 2023 | Opioid/Substance Use Disorders
The Department of Justice (DOJ) filed a lawsuit against AmerisourceBergen, accusing the company of partially fueling the opioid crisis by failing to report hundreds of thousands of suspicious orders. The lawsuit asks for potentially billions of dollars in financial...
Recent Comments